TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03429543

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 film-coated tablet of either Linagliptin or Empagliflozin matched placebo once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 1 film-coated tablet of either Linagliptin or Empagliflozin matched placebo once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 1 film-coated tablet of either Linagliptin or Empagliflozin matched placebo once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 1 film-coated tablet of either Linagliptin or Empagliflozin matched placebo once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Description: 1 film-coated tablet Linagliptin once daily, until end of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Description: 1 film-coated tablet Linagliptin once daily, until end of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: 1 film-coated tablet of Empagliflozin once daily, until end of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: 1 film-coated tablet of Empagliflozin once daily, until end of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: 1 film-coated tablet of Empagliflozin once daily, until end of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: 1 film-coated tablet of Empagliflozin once daily, until end of treatment.
Study: NCT01008124

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Liberatory Maneuver
Description: 3 cycles of the liberatory maneuver initial session.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo maneuver
Description: 3 cycles placebo maneuver initial session.
Study: NCT03854539

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transdermal Vagus Nerve Stimulation
Description: intermittent transdermal stimulation of the aurical vagus

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transdermal Vagus Nerve Stimulation
Description: intermittent transdermal stimulation of the aurical vagus

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transdermal Vagus Nerve Stimulation
Description: intermittent transdermal stimulation of the aurical vagus

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Transdermal Vagus Nerve Stimulation
Description: intermittent transdermal stimulation of the aurical vagus
Study: NCT00594594

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotic Lactobacillus GR-1 and RC-14
Description: Two capsules of Lactobacillus GR-1 and RC-14 daily for 12 months
Study: NCT04511065

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Newsletter using a virtual mode of delivery
Description: Newsletter creation where topics in the newsletter are chosen by participants in the intervention group.
Study: NCT00094107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib [AG-013736]
Description: VEGFR \[vascular endothelial growth factor Receptor\] and PDGFR \[Platelet-Derived Growth Factor Receptor\] inhibitor: Single agent AG-013736 starting dose 5 mg BID +/- 20% according to toxicity. Treatment until progression or unacceptable toxicity occurs.
Study: NCT00870298

Intervention type: DRUG
Group type: OTHER
Intervention: Trimethoprim/Sulfamethoxazole and Warfarin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethoprim/Sulfamethoxazole and Warfarin
Study: NCT00924404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xylitol
Description: 5% solution for sinus rinse

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: saline for sinus rinse
Study: NCT00454181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon-alpha
Description: 500 IU interferon-alpha lozenges taken 3 times per day for 24 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 200 mg lozenges containing anhydrous crystalline maltose taken three times per day for 24 weeks
Study: NCT01843270

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: actual body weight based size
Description: According randomized allocated group, the laryngeal mask airway is inserted based on actual or ideal body weight-based sizes before the surgery.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ideal body weight based size
Description: According randomized allocated group, the laryngeal mask airway is inserted based on actual or ideal body weight-based sizes before the surgery.
Study: NCT04607460

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JOGO Digital Therapeutics EMG Biofeedback for Lower Back Pain
Description: Use of the JOGO Digital Therapeutics EMG Biofeedback device for 8 weeks with specific exercises to target low back pain.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JOGO Digital Therapeutics EMG Biofeedback for Persistent Post Mastectomy Pain
Description: Use of the JOGO Digital Therapeutics EMG Biofeedback device for 4 weeks with specific exercises to mitigate persistent post mastectomy pain ahead of the surgery.
Study: NCT01205126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered to the participants receiving hydromorphone HCl or oxycodone HCl CR along with the study treatment to maintain necessary blinding.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered to the participants receiving hydromorphone HCl or oxycodone HCl CR along with the study treatment to maintain necessary blinding.
Study: NCT03264976

Intervention type: DIAGNOSTIC_TEST
Intervention: hematological examination, ophthalmic examination
Description: Hematological examination includes biochemical examination, routine coagulation test, HbA1c, C reactive protein (CRP)；Ophthalmic examination includes the basic situation and clinical diagnosis of eyes, ETDRS visual acuity chart score, intraocular pressure, OCT examination, OCTA examination, fundus photos, Optos wide angle fundus imaging.

Intervention type: DIAGNOSTIC_TEST
Intervention: hematological examination, ophthalmic examination
Description: Hematological examination includes biochemical examination, routine coagulation test, HbA1c, C reactive protein (CRP)；Ophthalmic examination includes the basic situation and clinical diagnosis of eyes, ETDRS visual acuity chart score, intraocular pressure, OCT examination, OCTA examination, fundus photos, Optos wide angle fundus imaging.
Study: NCT04607460

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JOGO Digital Therapeutics EMG Biofeedback for Migraine
Description: Use of the JOGO Digital Therapeutics EMG Biofeedback device for 6 weeks with specific exercises to target migraine pain.
Study: NCT01924559

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glidescope

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Supraglottic Airway
Study: NCT01822080

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo once daily by mouth
Study: NCT03057665

Intervention type: DEVICE
Intervention: Atomic Biomagnetometer
Description: Measure magnetic field of fetal heartbeat
Study: NCT01924559

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Supraglottic Airway
Study: NCT00640315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat (Adempas, BAY63-2521) 1.0 mg
Description: 1.0 mg BAY63-2521 will be given twice per subject, as single dose administration during the hemodynamic investigation (on study day 1) and during the lung function testing (on study day 3).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat (Adempas, BAY63-2521) 2.5 mg
Description: 2.5 mg BAY63-2521 will be given twice per subject, as single dose administration during the hemodynamic investigation (on study day 1) and during the lung function testing (on study day 3).
Study: NCT00922740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VA106483
Description: Placebo on Day 1, 1 mg VA106483 on Day 3, 2 mg VA106483 on Day 5 and 4 mg VA106483 on Day 7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VA106483
Description: Placebo on Day 1, 1 mg VA106483 on Day 3, 2 mg VA106483 on Day 5 and 4 mg VA106483 on Day 7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VA106483
Description: Placebo on Day 1, 1 mg VA106483 on Day 3, 2 mg VA106483 on Day 5 and 4 mg VA106483 on Day 7

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo on Day 1, 1 mg VA106483 on Day 3, 2 mg VA106483 on Day 5 and 4 mg VA106483 on Day 7
Study: NCT02641158

Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: After screening HCV antibody positive, participants will receive an appointment and reminder card to return for their HCV RNA results. If HCV RNA positive, study staff will attempt to make an appointment for the participant's next step in the HCV continuum. If a participant attends the next step visit, the participant would be subject to whatever is the local standard of care at that clinic/agency from that point forward.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care Facilitation Group
Description: The same will occur for intervention participants, yet an HCV care facilitator will motivate them to return for their HCV RNA results; appointment reminders will be made prior to the next step visit; follow-up contact will be made for missed appointments; and the HCV care facilitator will coordinate and link the participant to available community resources (e.g., mental health, housing agencies) by scheduling appointments, arranging transportation, and helping to complete any clinic registration (or other) paperwork that agencies may require to access services.
Study: NCT00610246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib orally for one week prior to radiation, then concomitantly for two weeks with radiation and then for one week following completion of radiation. Each anatomic cohort will dose escalate independently. Dose level 1 is 200mg of sorafenib. If full oral dose (400mg orally, twice a day) is reached in a given cohort then an additional dose level will open where sorafenib treatment is extended following radiation for a total of eight weeks.
Study: NCT00696787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine Sustained Release (DVS SR)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lyrica® (Pregabalin)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01403220

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hemodiafiltration first
Description: Patients will alternate consecutive dialysis sequences between hemodiafiltration and hemofiltration, but starting with hemodiafiltration.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hemofiltration first
Description: Patients will alternate consecutive dialysis sequences between hemodiafiltration and hemofiltration, but starting with hemofiltration.
Study: NCT01971047

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regular Insulin
Description: Group 1 Treatment Arm,Follow dosing for BG \>180 per the following formula:~1. Patients with Type 2 Diabetes to receive dosage based on the formula: (BG-120)/30= # units of insulin~2. Patients with Type 1 Diabetes to receive dosage based on the formula: (BG-120)/40=# units of insulin~3. Patients with Type 1 Diabetes and Type 2 Diabetes over the age of 70 or with chronic kidney disease to receive dosage based on the formula: (BG-120)/50=# units of insulin~4. Consider repeating dose if BG\>240 mg/dl after 2 hours of initial dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humalog
Description: Group 2 treatment arm. Follow dosing for Blood glucose \> 180, per the following formula:~1. Patients with Type 2 Diabetes to receive dosage based on the formula: (BG-120)/30= # units of insulin~2. Patients with Type 1 Diabetes to receive dosage based on the formula: (BG-120)/40=# units of insulin~3. Patients with Type 1 Diabetes and Type 2 Diabetes over the age of 70 or with chronic kidney disease to receive dosage based on the formula: (BG-120)/50=# units of insulin~4. Consider repeating dose if BG\>240 mg/dl after 2 hours of initial dose
Study: NCT03645863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-6548
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-6548
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-6548
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron supplement A
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron supplement B
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron supplement C
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron supplement D
Description: Oral tablet
Study: NCT04465981

Intervention type: DIAGNOSTIC_TEST
Intervention: Sampling
Description: Test is to validate the utility of INanoBio's automated protein arrays in detecting antibodies against SARS-CoV-2 proteins.

Intervention type: DIAGNOSTIC_TEST
Intervention: Sampling
Description: Test is to validate the utility of INanoBio's automated protein arrays in detecting antibodies against SARS-CoV-2 proteins.
Study: NCT03892018

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oraxol
Description: Oraxol will be supplied as paclitaxel capsules and HM30181AK-US tablets.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oraxol
Description: Oraxol will be supplied as paclitaxel capsules and HM30181AK-US tablets.
Study: NCT04486365

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bifocal bone transport.
Description: The bifocal approach is a single osteotomy to create one transported bone segment between the osteotomy and the defect.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trifocal bone transport
Description: The trifocal approach is two osteotomies creating two separate transported bone segments.
Study: NCT03503695

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sterile acupuncture semi-permanent (ASP) gold needles
Study: NCT00996489

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coaptite®
Description: Calcium hydroxylapatite particles suspended in an aqueous based gel carrier
Study: NCT01473407

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epoetin Hospira
Description: Variable dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Epogen (Amgen)
Description: Variable dose
Study: NCT00679133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGCD265
Description: Oral daily administration; 7 days on / 7 days off
Study: NCT05229536

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal ACYW135 Polysaccharide Conjugate Vaccine
Description: Group 1: 3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 10 µg each of Serogroup A, C, Y, and W135 polysaccharide conjugate.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal ACYW135 Polysaccharide Conjugate Vaccine
Description: Group 2: 3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 5 µg each of Serogroup A, C, Y, and W135 polysaccharide conjugate.
Study: NCT02754765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delamanid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delamanid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delamanid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofazimine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofazimine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofazimine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazinamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazinamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazinamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazinamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazinamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control arm MDR-TB regimen, consistent with WHO guidelines
Description: Control arm MDR-TB regimen, consistent WHO guidelines
Study: NCT00455156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 150 mg of Nestorone and 15 mg of ethinyl estradiol (150/15 NES/EE CVR)
Description: 150 mg of Nestorone and 15 mg of ethinyl estradiol (150/15 NES/EE CVR), administered via vaginal ring, used on a 21/7 days in/out schedule for no more than one year.
Study: NCT02802904

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet: Palm olein IV64
Description: Each subject received a palm olein-based run in diet for 2 weeks, followed by random assignment test fat Palm Olein IV64 which was incorporated into daily snacks (\~50g of test fats, brownies (\~15g test fat each) for breakfast and 4 pieces cookies (\~5g test fat each) with low fat palm olein based background diet daily.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet: Cocoa butter
Description: Each subject received a palm olein-based run in diet for 2 weeks, followed by random assignment test fat cocoa butter which was incorporated into daily snacks (\~50g of test fats, brownies (\~15g test fat each) for breakfast and 4 pieces cookies (\~5g test fat each) with low fat palm olein based background diet daily.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet: Virgin olive oil
Description: Each subject received a palm olein-based run in diet for 2 weeks, followed by random assignment test fat virgin olive oil which incorporated into daily snacks (\~50g of test fats, brownies (\~15g test fat each) for breakfast and 4 pieces cookies (\~5g test fat each) with low fat palm olein based background diet daily.
Study: NCT01573104

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proteomic assay
Description: Urine will be taken for proteomic assay at baseline, day 1 and day 2

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Point of care testing of blood for NGAL/BNP at baseline, day 1 and day 2

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biomarker sampling
Description: Urine will be taken at baseline and day 1, day 2 for evaluation of renal biomarkers at later date
Study: NCT02453555

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Linagliptin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Linagliptin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linagliptin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Empagliflozin placebo + linagliptin placebo low dose
Description: Matching placebo empagliflozin + linagliptin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin placebo + linagliptin placebo low dose
Description: Matching placebo empagliflozin + linagliptin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin + linagliptin low dose
Description: tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Empagliflozin + linagliptin low dose
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin placebo
Description: Matching placebo linagliptin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin placebo
Description: Matching placebo linagliptin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Linagliptin placebo
Description: Matching placebo linagliptin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin + linagliptin high dose
Description: tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Empagliflozin + linagliptin high dose
Description: tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Empa + lina highdose placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empa + lina highdose placebo
Study: NCT01008085

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stentys coronary stent
Description: Self-expanding Nitinol stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Balloon-expandable stent
Description: VISION/Driver
Study: NCT00136305

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pictorial asthma action plan

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Written asthma action plan
Study: NCT02680951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Administered orally on a once daily schedule based on the dose level assigned to the patient at enrollment (60, 80, or 100mg/m2/day). Patients may adjust the time they take dasatinib as long as they take the drug approximately every 24 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Administered orally on a once daily schedule based on the dose level assigned to the patient at enrollment (60, 80, or 100mg/m2/day). Patients may adjust the time they take dasatinib as long as they take the drug approximately every 24 hours
Study: NCT01767623

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vemurafenib
Description: Vemurafenib orally BID 960 or 720 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Vemurafenib orally BID 960 or 720 mg.
Study: NCT02540993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finerenone (BAY94-8862)
Description: Oral tablet; starting dose at 10 mg for subjects with an eGFR between 25 to \< 60 mL/min/1.73m² at the Screening Visit; starting dose at 20 mg for subjects with an eGFR ≥ 60 mL/min/1.73m² at the Screening Visit; dose could be up-titrated from Month 1 onwards or down-titrated at any time during the study; once daily in the morning, until the trial was completed provided there were no safety grounds for discontinuing treatment